# Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

> **NCT01410565** · PHASE3 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 66 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Apaziquone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01410565
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** Business reason
- **Last updated:** 2016-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410565, "Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01410565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*